Cosette Pharmaceuticals Buys Assertio Holdings Product Portfolio

Bridgewater’s Cosette Pharmaceuticals struck a deal on April 9 to acquire U.S. sales and distribution rights to seven branded products from Assertio Holdings Inc., the company confirmed. Financial terms weren’t disclosed.

Cosette’s got about 350 employees and is backed by private equity firm Avista Healthcare Partners and investment manager Hamilton Lane. The purchase adds six branded non-steroidal anti-inflammatory drugs covering pain, inflammation and migraine treatment, but the product drawing the most attention is SYMPAZAN.

SYMPAZAN is the sole FDA-approved oral film formulation of clobazam, a drug treating seizures linked to Lennox-Gastaut Syndrome, a rare and severe form of epilepsy that accounts for 1 to 10 percent of childhood epilepsy cases and 1 to 2 percent of all epilepsy diagnoses. It’s cleared for patients as young as 2 years old. Nothing else on the market does what it does. Patent protection on SYMPAZAN runs until 2040, meaning Cosette has a long, uncontested runway ahead on what is already an orphan-adjacent product with genuine clinical value.

“This acquisition reflects Cosette’s strategic approach to expanding our branded portfolio,” said Apurva Saraf, president and CEO of Cosette Pharmaceuticals. “It adds immediate scale through branded, on-market products and includes SYMPAZAN.”

Saraf also framed the transaction as proof that Cosette can “execute strategic transactions propelling our growth.” That’s consistent with what Avista-backed companies tend to signal before they start shopping again.

The six other products coming from Assertio aren’t obscure. INDOCIN, the indomethacin formulation available in both oral and suppository form. SPRIX, a ketorolac tromethamine nasal spray. ZIPSOR, diclofenac potassium in liquid-filled capsules. CAMBIA, diclofenac potassium as an oral solution. And OTREXUP, a subcutaneous methotrexate injection. These are Familiar products to anyone who’s worked in rheumatology or pain management. The kind of names that don’t need explaining in a Bergen County waiting room.

The deal structure includes a transition period covering manufacturing handoffs, supply chain responsibilities, pharmacovigilance, quality assurance and regulatory transfers between Assertio and Cosette. That’s standard for specialty pharma acquisitions, but it’s not automatic. Pharmacovigilance system integrations can get messy fast, especially when field sales teams are absorbing new product training mid-year while trying to hit quarterly numbers.

For Cosette’s 350 employees, more products typically means commercial team expansion, not the reverse. The company didn’t announce any workforce changes alongside the deal. Still, integration periods are where the hard work actually happens, and that’s where companies either deliver on what they announced or don’t.

This is a meaningful moment for a New Jersey specialty pharma firm that, until now, hasn’t gotten much attention beyond the Bridgewater pharma corridor. Cosette’s been building quietly. The Assertio portfolio, SYMPAZAN in particular, gives them something with a long patent shelf life and no direct generic threat until 2040. That’s not a small thing.

The original announcement was first reported by ROI-NJ on April 9, 2026.